<DOC>
	<DOCNO>NCT02908763</DOCNO>
	<brief_summary>HBsAg Loss/Seroconversion uncommon Low replicative chronic HBV infection patient . The purpose study investigate ability peginterferon alpha achieve HBsAg loss/seroconversion therapy Low replicative chronic HBV infection patient Low Level HBsAg .</brief_summary>
	<brief_title>HBsAg Loss/Seroconversion Low Replicative Chronic Hepatitis B Virus ( HBV ) Infection Patients</brief_title>
	<detailed_description>Low replicative chronic HBV infection patient low Level HBsAg enrol out-patient department 3rd Affiliated Hospital Sun Yat-sen University . All HBsAg positive anti-HBs negative 6 month HBV DNA &lt; 2000 IU/mL HBsAg level ≤1000 IU/mL . All patient liver disease contraindication interferon therapy . After give informed consent , patient treat weekly subcutaneous injection alfa-2a 180 micrograms/week peginterferon alfa-2b 80 micrograms/week . The use immune suppressive regulatory drug antiviral drug prohibit course study . In study , treatment endpoint HBsAg loss ( ＜0.05 IU/mL ) anti-HBs positive ( ＞10 milli-International unit ( mIU ) /mL ) define seroconversion . Depending decline HBsAg level , treatment either continue prolonged period ( 96 week ) endpoint achieve , terminate case nonresponse . Treatment proceed HBsAg level continue decline HBsAg seroconversion achieve anti-HBs level 200 mIU/ml . If patient willing extend treatment , therapy end time HBsAg loss , stop without decline HBsAg level .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . Hepatitis B surface antigen ( HBsAg ) positive &lt; 1000 IU/mL . 2 . Hepatitis B surface antibody ( HBsAb ) negative . 3 . Hepatitis B e antigen ( HBeAg ) negative . 4 . Hepatitis B virus DNA &lt; 2000 IU/mL . 5 . Absence previous antiviral therapy . 1 . Patients active alcohol and/or drug consumption . 2 . Patients liver cirrhosis , Hepatocellular Carcinoma malignancy . 3 . Patients factor cause liver disease . 4 . Pregnant lactating woman . 5 . Patients concomitant HIV infection congenital immune deficiency disease . 6 . Patients diabetes , autoimmune disease . 7 . Patients important organ dysfunction . 8 . Patients mental illness . 9 . Patients receive antineoplastic immunomodulatory therapy past 12 month . 10 . Patients ca n't come back clinic followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Peginterferon Alpha</keyword>
</DOC>